Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Psyche Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Psyche Pharmaceuticals aims to commercialize a technique for the chemical synthesis of proteins, which theoretically allows for the insertion of unnatural amino acids and thus, custom design of therapeutic proteins. The new method combines aspects of solution-based and solid-phase approaches to peptide synthesis, and also harnesses mass spectroscopy. For now, the start-up aims to sell peptides, particularly chemokines, into the research market.

You may also be interested in...



Protein Production Start-Ups

Should a disruptive protein production technology emerge, the current interest in developing large-molecule therapeutics assures there would be many takers.

Glycofi Inc.

One of the biggest commercial challenges that biotechnology firms faced in the 1980s has only just been resolved: Glycofi has come up with a way to manufacture human therapeutic proteins in yeast and other fungal protein expression systems. The firm figures the first adopters will be companies that have identified proteins they know are pharmacologically active, but which cannot be produced in sufficient quantity with now-standard mammalian cell culture techniques.

Albany Molecular's Next Act

In the fast-growing chemistry services market, Albany Molecular has proven itself a steady and, in recent times, superlative performer. Albany Molecular is capitalizing on its growing revenue stream and strong market performance by building up chemistry capabilities to provide one-stop, albeit specialty, shopping. But the company's growth and above-average margins stem largely from its one major royalty deal, on Allegra--and the company has been spending its time on services, not on at-risk deals.Recent acquisitions position Albany Molecular to provide more proprietary technologies: the key is whether the company's management is willing to take the financial risk of deals in which it has to fund its own early development in order to win an important piece of a product's upside and thus boost it service-company margins.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel